TF-1 Cells

Unit

5 x 10^6 cells/ml

Cell Type

Tumor Cells

Tissue Type

Leukemia cell lines

Organism

Human

Donor History

Erythroleukemia

Growth Properties

Suspension

Growth Conditions

Culture medium: RPMI 1640

,

w: 2.1 mM stable Glutamine

,

w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS

,

5 ng/ml GM-CSF; for long-term culture: IL-3. Seeding density: > 2 x 10⁵ cells/ml. Freeze medium: As a cryopreservation medium

,

we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability

,

or CM-1 (Cytion catalog number 800100)

,

which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C

,

5% CO2

,

humidified atmosphere.

Immortalization Method
Full Information

https://www.cytion.com/TF-1-Cells/300434

SKU: 300434 Kategorie: ,
Mgr. Otakar Fišer
Máte otázky k tomuto produktu? Kontaktujte našeho specialistu.
Mgr. Otakar Fišer
Produktový manažer - Life Science
Popis

TF-1 cells are erythroblasts isolated from the bone marrow of a 35-year-old Asian male diagnosed with severe pancytopenia in 1987. These cells are a pivotal model for studying the complex processes of proliferation and differentiation within myeloid progenitor cells. As a cell line, TF-1 is heavily utilized in hematological research to understand the underlying mechanisms that govern cell cycle regulation and development in myeloid lineages.

In addition to their primary role in hematopoietic research, TF-1 cells serve as a robust system for examining the impact of various cytokines on cell survival and growth. Their dependence on specific growth factors such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-3 (IL-3) for proliferation makes them an excellent tool for studying cytokine-mediated signaling pathways. This characteristic also makes TF-1 cells useful in evaluating the efficacy of new pharmacological agents that aim to modulate these pathways, thereby contributing significantly to therapeutic advances in treating myeloid disorders and other related diseases.

O značce

Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.

Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.